Prevalence of Conjunctivitis and Indentification of Risk Factors With and Without Prophylactic Antibiotic Treatment in Neonates

Conjunctivitis Incidence in the Newborn Within the First Week of Life: Impact of the Prophylactic Use of Rifamycine(CRY NOT).

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03528915

Acronym

CRY-NOT

Enrollment

881

Registered

2018-05-18

Start date

2015-09-09

Completion date

2016-07-24

Last updated

2019-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ophthalmia Neonatorum

Keywords

neonate, infant; eyewash; delivery room; prophylaxis; risk factor's

Brief summary

The French guidelines for the use of Rifamycine eye drops in delivery room to prevent neonatal conjunctivitis have been actualized. Only newborns exposed to risk factors of conjunctivitis should be treated, compared to previous guidelines, treating all newborns. currently, there are no data describing risk factors for neonatal conjunctivitis. This study evaluated the incidence of conjunctivitis with or without Rifamycine eye drops treatment in the delivery room. Then risk factors for neonatal conjunctivitis where analyzed.

Interventions

OTHERRifamycine treatment

Phone prospecting: occurrence of conjunctivitis in newborns treated with rifamycine treatment in delivery room.

OTHERwhithout Rifamycine treatment

Phone prospecting: occurrence of conjunctivitis in newborns did not receive eye drop treatment in delivery room according to new guidelines.

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

36 Weeks to 36 Weeks

Healthy volunteers

Inclusion criteria

* Newborns at the University Hospital of Amiens\> 36SA, * Admitted in maternity at the exit of nursery

Exclusion criteria

* Newborns at the Amiens University Hospital \<36SA * Eye drops for any medical reason within the first day of life.

Design outcomes

Primary

Measure	Time frame
Occurrence of conjunctivitis during the first 8 days of life in newborns	8 days

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026